TSFLAB02a:	Subjects With =1 [Laboratory Category] Laboratory Values With Elevated or Low Values Meeting Specified Levels Based on Worst On-treatment Value by [Subgroup]; Safety Analysis Set (Study jjcs - core)						
 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
Laboratory Test 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
  Threshold Level, n (%) 	N=53 	N=73 	N=59 	  	  	
Age: ≥18 to <65 years 	8 	5 	7 	 	 	
 	  	  	  	  	  	
Calcium, low 	 	 	 	 	 	
N 	8 	5 	6 	 	 	
Level 1 (<2.096 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<1.996 mmol/L) 	2 (25.0%) 	1 (20.0%) 	2 (33.3%) 	-8.3 (-56.5, 39.9) 	-13.3 (-64.8, 38.2) 	
Level 3 (<1.871 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	 	 	 	 	 	
Glucose, low 	 	 	 	 	 	
N 	8 	4 	7 	 	 	
Level 1 (<3.89 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<3.00 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Age: ≥65 to <75 years 	16 	17 	19 	 	 	
 	  	  	  	  	  	
Calcium, low 	 	 	 	 	 	
N 	14 	12 	19 	 	 	
Level 1 (<2.096 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<1.996 mmol/L) 	2 (14.3%) 	3 (25.0%) 	5 (26.3%) 	-12.0 (-39.0, 15.0) 	-1.3 (-32.8, 30.2) 	
Level 3 (<1.871 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	 	 	 	 	 	
Glucose, low 	 	 	 	 	 	
N 	13 	12 	19 	 	 	
Level 1 (<3.89 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<3.00 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Age: ≥75 years 	29 	51 	33 	 	 	
 	  	  	  	  	  	
Calcium, low 	 	 	 	 	 	
N 	28 	44 	31 	 	 	
Level 1 (<2.096 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<1.996 mmol/L) 	13 (46.4%) 	11 (25.0%) 	6 (19.4%) 	27.1 (4.0, 50.2) 	5.6 (-13.3, 24.5) 	
Level 3 (<1.871 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
 	 	 	 	 	 	
Glucose, low 	 	 	 	 	 	
N 	26 	42 	30 	 	 	
Level 1 (<3.89 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Level 2 (<3.00 mmol/L) 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	

Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.] 	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: On-treatment is defined as treatment-emergent laboratory values obtained after the first dose and within [30 days] following treatment discontinuation. [Treatment-emergent values are those that worsened from baseline.]	
Note: Subjects are counted once per laboratory test category (ie, low, high) based on the worst categorization. 	: Subjects are counted once per laboratory test category (ie, low, high) based on the worst categorization.	: Subjects are counted once per laboratory test category (ie, low, high) based on the worst categorization.	: Subjects are counted once per laboratory test category (ie, low, high) based on the worst categorization.	: Subjects are counted once per laboratory test category (ie, low, high) based on the worst categorization.	: Subjects are counted once per laboratory test category (ie, low, high) based on the worst categorization.